BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety
Completed
- Conditions
- Prostate Cancer
- Interventions
- Drug: Radium-223-dichloride (Xofigo, BAY88-8223)
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 103
- Registration Number
- NCT04681144
- Locations
- 🇨🇴
Many Locations, Multiple Locations, Colombia
A Study to Learn More About How Acarbose and Metformin Work When Taken Together and How Safe They Are in Indian Patients Who Were Recently Diagnosed With Type 2 Diabetes (T2D)
Active, not recruiting
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: BAY81-9783 (Acarbose/Metformin)
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2000
- Registration Number
- NCT04665570
- Locations
- 🇮🇳
Many locations, Multiple Locations, India
A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.
Phase 2
Withdrawn
- Conditions
- Chronic Kidney DiseaseDiabetic Kidney Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2021-05-21
- Lead Sponsor
- Bayer
- Registration Number
- NCT04661917
- Locations
- 🇫🇮
Päijät-Hämeen keskussairaala, Lahti, Finland
🇦🇹Landeskrankenhaus Feldkirch, Feldkirch, Vorarlberg, Austria
🇦🇹Zentrum f. klinische Studien Dr. Hanusch GmbH, Wien, Austria
Mass Balance Study of [14C]-NT-814 Oral Suspension in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: [14C]-NT-814
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 6
- Registration Number
- NCT04654897
- Locations
- 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom
A Study to Learn What Participants Think of Treatment With Betamethasone Plus Loratadine to Treat Their Acute Allergic Rhinitis, Also Known as Hay Fever in Mexico
Completed
- Conditions
- Rhinitis, Allergic
- Interventions
- Other: Online survey
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 153
- Registration Number
- NCT04645979
- Locations
- 🇲🇽
Many locations, Multiple Locations, Mexico
A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain
Phase 2
Terminated
- Conditions
- Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 154
- Registration Number
- NCT04641273
- Locations
- 🇩🇰
Kolding Sygehus, Kolding, Denmark
🇨🇿NEUROHK s.r.o, Chocen, Czechia
🇨🇿Vestra Clinics s.r.o., Rychnov nad Kneznou, Czechia
A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD).
Completed
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 330
- Registration Number
- NCT04641234
- Locations
- 🇧🇪
Many Locations, Multiple Locations, Belgium
Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 215
- Registration Number
- NCT04614246
- Locations
- 🇺🇸
Physician Care Clinical Research, Sarasota, Florida, United States
🇺🇸Medisense, Inc., Atlanta, Georgia, United States
🇺🇸HWC Women's Research Center, Englewood, Ohio, United States
Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS)
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT04609943
- Locations
- 🇩🇪
Universitätsklinikum Giessen und Marburg, Gießen, Hessen, Germany
🇩🇪Klinikum der Stadt Köln gGmbH - Krankenhaus Merheim, Köln, Nordrhein-Westfalen, Germany
🇩🇪Sana-Klinikum Remscheid|Kardio, Angio, Pneumo u. Intensivmed, Remscheid, Nordrhein-Westfalen, Germany
Survey on Menstrual Symptoms, Health Related Quality of Life and Work Productivity in Patients Suffering From Pain During Menstruation (Dysmenorrhea) in Japan
Completed
- Conditions
- Dysmenorrhea
- Interventions
- Drug: NSAIDs and/or Chinese medicine (CM)Drug: LEP
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 397
- Registration Number
- NCT04607382
- Locations
- 🇯🇵
Multiple Facilities, Multiple Locations, Japan
© Copyright 2025. All Rights Reserved by MedPath